MDR-1 HAPLOTYPES HAVE ONLY A MINOR INFLUENCE ON TACROLIMUS DOSE REQUIREMENT IN RENAL TRANSPLANT RECIPIENTS.

2006 ◽  
Vol 82 (Suppl 2) ◽  
pp. 490
Author(s):  
&NA;
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Dose Requirement ◽  
Minor Influence ◽  
A Minor ◽  
Tacrolimus Dose ◽  
Mdr 1

scholarly journals Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids

2003 ◽  
Vol 56 (3) ◽  
pp. 327-330 ◽  
Author(s):  
Dennis A. Hesselink ◽  
Hien Ngyuen ◽  
Marike Wabbijn ◽  
Peter J. H. Smak Gregoor ◽  
Ewout W. Steyerberg ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Dose Requirement ◽  
Tacrolimus Dose

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

2006 ◽  
Vol 16 (9) ◽  
pp. 659-665 ◽  
Author(s):  
Jean Nicholas Roy ◽  
Azemi Barama ◽  
Charles Poirier ◽  
Bernard Vinet ◽  
Michel Roger
Keyword(s):  
Renal Transplant ◽  
Genetic Influences ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Tacrolimus Pharmacokinetics ◽  
Mdr 1

Tacrolimus Dose in Black Renal Transplant Recipients

2007 ◽  
Vol 83 (7) ◽  
pp. 997-999 ◽  
Author(s):  
Nidyanandh Vadivel ◽  
Ashwani Garg ◽  
David W. Holt ◽  
Rene W. S. Chang ◽  
Iain A. M. MacPhee
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Tacrolimus Dose

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

2010 ◽  
Vol 11 (10) ◽  
pp. 1389-1402 ◽  
Author(s):  
Ping Wang ◽  
Yong Mao ◽  
Juan Razo ◽  
Xiaobo Zhou ◽  
Stephen TC Wong ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Clinical Factors ◽  
Tacrolimus Dose

Time dependent expression of MDR-1 in stable male renal transplant recipients

2005 ◽  
Vol 77 (2) ◽  
pp. P62-P62
Author(s):  
K TORNATORE ◽  
D BRAZEAU ◽  
K DOLE ◽  
K GILLIS ◽  
N LECA ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Time Dependent ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Mdr 1

Low Tacrolimus Dose Requirements in Renal Transplant Recipients in the Omani Population: Implications for Pharmacogenetics?

2005 ◽  
Vol 37 (7) ◽  
pp. 2911-2912 ◽  
Author(s):  
N. Mohsin ◽  
A. Pakkyara ◽  
M. Budruddin ◽  
F. Obaid ◽  
A. Kumar ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Tacrolimus Dose

scholarly journals No Influence of the MDR-1 C3435T Polymorphism or a CYP3A4 Promoter Polymorphism (CYP3A4-V Allele) on Dose-adjusted Cyclosporin A Trough Concentrations or Rejection Incidence in Stable Renal Transplant Recipients

2001 ◽  
Vol 47 (6) ◽  
pp. 1048-1052 ◽  
Author(s):  
Nicolas von Ahsen ◽  
Michael Richter ◽  
Clemens Grupp ◽  
Burckhardt Ringe ◽  
Michael Oellerich ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Cyclosporin A ◽  
Promoter Polymorphism ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
C3435t Polymorphism ◽  
Trough Concentrations ◽  
Cyp3a4 Enzyme ◽  
Mdr 1

Abstract Background: A substantial proportion of the variability in the absorption and clearance of cyclosporin A (CsA) after oral administration has been attributed to variability in liver cytochrome P-450 3A4 (CYP3A4) activity and intestinal P-glycoprotein (P-gp) concentration. A polymorphism in the CYP3A4 promoter region, termed “variant” allele CYP3A4-V, was postulated to be associated with altered CYP3A4 enzyme activity. A polymorphism in exon 26 (C3435T) of the multidrug resistance-1 (MDR-1) gene was correlated with intestinal expression and in vivo activity of P-gp. Methods: We investigated the occurrence of both polymorphisms in 124 stable Caucasian renal transplant recipients (>6 months after transplantation) on CsA as the primary immunosuppressant. Real-time, rapid-cycle PCR methods were developed and used for genotyping. Results: The estimated allele frequencies for the MDR-1 C3435T allele (54%) and the CYP3A4-V allele (4.8%) were similar to those reported for Caucasian populations. No significant differences were found for the CsA doses needed to maintain similar CsA trough concentrations in patients with and without the CYP3A4-V allele or in patients with different MDR-1 C3435T genotypes. Furthermore, neither of the polymorphisms investigated was associated with renal function as assessed by creatinine plasma concentration or, in a retrospective analysis, the incidence of acute rejection. Conclusions: These findings suggest that the MDR-1 C3435T mutation and the CYP3A4-V variant are not major determinants of CsA efficacy in renal transplant recipients.

Sign in / Sign up

Export Citation Format

Share Document